DTWD2 Knockout HGC-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the HGC-27 human gastric carcinoma cell line. This product provides a heterogeneous pool of cells with targeted disruption of the DTWD2 gene, enabling loss-of-function studies in a gastric adenocarcinoma context. The polyclonal format avoids clonal selection artifacts and is suitable for pooled functional assays, offering a robust model for investigating DTWD2 biology.
Hosted in the HGC-27 cell line, this model retains the biological features of poorly differentiated gastric epithelial cells originally derived from a metastatic lymph node of a gastric adenocarcinoma patient. HGC-27 cells are adherent and widely used as an in vitro system for gastric cancer research, including studies of tumor progression, metastasis, and therapeutic response. Their undifferentiated phenotype and metastatic origin make them a relevant substrate for exploring gene function in advanced gastric malignancies.
DTWD2 encodes a poorly characterized protein containing a DTW domain, a module often associated with ubiquitin-related processes. While its precise molecular function remains undefined, the presence of the DTW domain suggests a potential role in the ubiquitin-proteasome system. In this pathway, ubiquitin is activated by an E1 enzyme, transferred to an E2 conjugating enzyme, and ligated to substrates by an E3 ligase, ultimately targeting proteins for degradation by the 26S proteasome. DTWD2 may act as an adaptor or regulatory factor in this cascade, influencing protein turnover and downstream signaling.
In the context of HGC-27 gastric cancer cells, knockout of DTWD2 provides a valuable platform to dissect its contributions to cellular processes such as proliferation, apoptosis, migration, and invasion. Because ubiquitin-mediated proteolysis governs key oncogenic and tumor suppressor networks, DTWD2 disruption may reveal previously unrecognized vulnerabilities in gastric adenocarcinoma. This model thus supports investigations into DTWD2??s involvement in cancer progression and its potential as a therapeutic target.
Typical applications include functional characterization of DTWD2 via Western blotting and RT-qPCR to confirm knockout efficiency, phenotypic assays such as cell proliferation, colony formation, and transwell migration, as well as flow cytometric analysis of apoptosis and cell cycle. Advanced studies may employ RNA-seq for transcriptome-wide profiling and ubiquitination assays to probe direct enzymatic activity. This polyclonal knockout cell population is an ideal starting point for elucidating DTWD2 biology in gastric cancer. For further technical information or ordering assistance, please contact Ascent Research.
